Supporting data for “Gut Microbiome Regulates Immunotherapy Response through Systemic Immune Environment in Patients with Hepatocellular Carcinoma”

This dataset was originated from the thesis entitled "Gut Microbiome Regulates Immunotherapy Response through Systemic Immune Environment in Patients with Hepatocellular Carcinoma", including metagenomic sequencing and flow cytometry data.   Immune checkpoint inhibitors (ICIs) have emerged as the pillars of anticancer treatment for hepatocellular carcinoma (HCC). Nevertheless, only few patients could benefit from ICIs. Most efforts have been directed toward identifying biomarkers of ICIs response more than 6 months, while biomarkers to predict long-term benefits are scarce. Gut microbiota is related with the incidence, progression of several cancer types. There is also a crosstalk between gut microbiota and immune systems, which has the potential of predicting immunotherapy response. In this study, we performed an integrative analysis of gut commensal bacteria and systemic immune, to assess their prospective role on outcomes of HCC patients treated with immunotherapy and establish their causal links.

本数据集源自题为《通过系统性免疫环境调节肝癌患者免疫治疗反应的肠道微生物组》的论文，包括宏基因组测序和流式细胞术数据。免疫检查点抑制剂（ICIs）已成为肝癌（HCC）抗癌治疗的基石。然而，仅有少数患者能从中获益。大部分研究工作集中于识别超过6个月的ICIs响应的生物标志物，而预测长期获益的生物标志物却寥寥无几。肠道微生物群与多种癌症类型的发病率和进展密切相关。此外，肠道微生物群与免疫系统之间存在相互作用，具有预测免疫治疗反应的潜力。在本研究中，我们对肠道共生细菌和系统性免疫进行了综合分析，以评估它们在免疫治疗肝癌患者预后中的作用及其因果关系。